Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$166M |
| 2 |
Roivant Sciences
ROIV
|
+$137M |
| 3 |
Immunovant
IMVT
|
+$130M |
| 4 |
BridgeBio Pharma
BBIO
|
+$96.5M |
| 5 |
Baidu
BIDU
|
+$94.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$498M |
| 2 |
Amazon
AMZN
|
+$398M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$372M |
| 4 |
Aon
AON
|
+$365M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$286M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.84% |
| 2 | Communication Services | 8.41% |
| 3 | Technology | 5.7% |
| 4 | Financials | 3.99% |
| 5 | Consumer Discretionary | 2.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Travere Therapeutics
TVTX
$6.19B
| – | – |
-12,000
| Closed | -$357K |
|
177
Tyra Biosciences
TYRA
$1.55B
| – | – |
-3,580,818
| Closed | -$137M |
|
178
UroGen Pharma
URGN
$2.29B
| – | – |
-11,000
| Closed | -$198K |
|
179
Visa
V
$693B
| – | – |
-840,710
| Closed | -$254M |
|
180
Veracyte
VCYT
$3.4B
| – | – |
-7,000
| Closed | -$225K |
|
181
Vir Biotechnology
VIR
$1.65B
| – | – |
-22,000
| Closed | -$197K |
|
182
Vertiv
VRT
$101B
| – | – |
-19,000
| Closed | -$4.76M |
|
183
Western Alliance Bancorporation
WAL
$8.69B
| – | – |
-73,000
| Closed | -$5.17M |
|
184
GeneDx Holdings
WGS
$2.6B
| – | – |
-5,000
| Closed | -$321K |
|
|
ALMS
185
Alumis Inc
ALMS
$3.13B
| – | – |
-11,000
| Closed | -$242K |
|
|
IRD
186
Opus Genetics
IRD
$337M
| – | – |
-1,000,000
| Closed | -$4.55M |
|
|
ONC
187
BeOne Medicines Ltd
ONC
$42.4B
| – | – |
-1,100
| Closed | -$327K |
|
|
TVRD
188
Tvardi Therapeutics
TVRD
$24.8M
| – | – |
-21,438
| Closed | -$68.2K |
|
|
BITW
189
Bitwise 10 Crypto Index ETF
BITW
$748M
| – | – |
-603,000
| Closed | -$26.9M |
|
|
RNA
190
Atrium Therapeutics
RNA
$226M
| – | – |
-349,360
| Closed | -$4.67M |
|
Similar funds
Thomas Steyer's Q2 2026 Portfolio in Review
As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.
- Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
- Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
- Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
- Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
- Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
- Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
- Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.